Baxter Commences Trial of Stem Cells in Coronary Artery Disease
Posted on: Wednesday, 8 March 2006, 12:00 CST
Baxter Healthcare has initiated a first-of-its-kind phase II trial in the US to evaluate blood-derived selected CD34+ stem cells in the treatment of chronic myocardial ischemia, a severe form of coronary artery disease.
Chronic myocardial ischemia (CMI) is a serious heart condition that involves narrowing of coronary arteries and results in limited blood flow to the heart, affecting hundreds of thousands of new patients each year.
This prospective, randomized, double-blind, placebo-controlled, multi-center study will involve approximately 150 adult patients who are currently on maximal medical therapy and are not suitable candidates for conventional procedures to improve blood flow to the heart, such as angioplasty, stents, or coronary artery bypass surgery.
"Baxter's sponsorship of this trial is consistent with our mission to be a leader in providing innovative life-saving therapies, and to pursue new opportunities where our technology can potentially help save and sustain lives," said Dr Norbert Riedel, Baxter's chief scientific officer.
Source: Datamonitor
Related Articles
- Improved Blood Circulation in Coronary Heart Disease
- Periodontitis linked to coronary heart disease
- A Homocysteine Metabolism-Related Dietary Pattern and the Risk of Coronary Heart Disease in Two Independent German Study Populations1
- Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent? Results From 25 Years of Follow-Up in the Renfrew and Paisley Survey
- CVBT Announces Cardio Vascu-Grow Appears to Be Safe and Well Tolerated As a Treatment for Coronary Heart Disease
- Scotland is Infamous for Its High Rate of Coronary Heart Disease
- Cocaine Can Harm Heart's Blood Vessels
- Immunocomb Chlamydia Bivalent Assay to Study Chlamydia Species- Specific Antibodies in Patients With Coronary Heart Disease
- A Model for Coronary Heart Disease and Stroke With Applications to Critical Illness Insurance Underwriting I: the Model
- Is Lipid-Lowering Therapy Underused By African Americans at High Risk of Coronary Heart Disease Within the VA Health Care System?
 |
 |
User Comments (0)
RSS Feeds